Ahmedabad-based pharmaceutical company Corona Remedies Limited has reported a 33% increase in its profit after tax (PAT) for the fiscal year 2026, reaching Rs 199 crore, according to a stock exchange filing. The company's annual revenues also saw a significant rise of 17.3%, amounting to Rs 1,403 crore during the fiscal year.
Key Financial Highlights
The company attributed this robust financial performance to strategic brand-building initiatives, operational efficiencies, and portfolio expansion. In a notable move during the year, Corona Remedies acquired Wokadine, marking its entry into the Rs 648-crore povidone-iodine market. This acquisition was funded through internal accruals, reflecting the company's strong cash position.
Strategic Initiatives and Portfolio Expansion
Corona Remedies also relaunched key brands in women's health and cardiovascular therapies, aiming to strengthen its presence in these therapeutic areas. Additionally, the company established a dedicated infertility segment team to focus on this growing market.
Fourth Quarter Performance
For the fourth quarter of FY26, the company's revenue rose by 20.2% to Rs 353 crore, indicating sustained momentum in the latter part of the fiscal year.
Management Commentary
Nirav Mehta, Managing Director and CEO of Corona Remedies, commented, "The company's focus on brand building, specialty segments like biosimilars and infertility, and portfolio expansion through acquisitions continues to strengthen our competitive positioning."
Outlook and Future Plans
With a strong balance sheet and a clear strategy focused on high-growth segments, Corona Remedies is well-positioned to continue its growth trajectory. The company's emphasis on operational efficiencies and strategic acquisitions is expected to drive further value for shareholders.
